RESEARCHER PROFILE

V.V. Masalova

← Back to Saint Petersburg State Pediatric Medical University

Saint Petersburg State Pediatric Medical University

Autoimmune and Inflammatory Disorders ResearchRheumatoid Arthritis Research and TherapiesKawasaki Disease and Coronary ComplicationsOcular Diseases and Behçet’s SyndromeSpondyloarthritis Studies and Treatments

V.V. Masalova works in Autoimmune and Inflammatory Disorders Research, Rheumatoid Arthritis Research and Therapies, Kawasaki Disease and Coronary Complications, Ocular Diseases and Behçet’s Syndrome, Spondyloarthritis Studies and Treatments. Recorded institutional associations include Saint Petersburg State Pediatric Medical University.

67Publications

320Citations

8H-index

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

← Return to the university profile

V.V. Masalova

Saint Petersburg State Pediatric Medical University

Selected research works

Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis

Distinguishing Between Multisystem Inflammatory Syndrome, Associated With COVID-19 in Children and the Kawasaki Disease: Development of Preliminary Criteria Based on the Data of the Retrospective Multicenter Cohort Study

The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience

Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use.

Heart Involvement in Multisystem Inflammatory Syndrome, Associated With COVID-19 in Children: The Retrospective Multicenter Cohort Data

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis

Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis

Determination of Risk Factors for Severe Life-Threatening Course of Multisystem Inflammatory Syndrome Associated with COVID-19 in Children

Current approaches to diagnosing and treating macrophage activation syndrome in children with rheumatic diseases

Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study

Reasons for inactive disease and flare in systemic onset juvenile idiopathic arthritis patients during tocilizumab treatment.

COVID-19 Associated Vasculitis Confirmed by the Tissues RT-PCR: A Case Series Report

Using HScore for Evaluation of Hemophagocytosis in Multisystem Inflammatory Syndrome Associated with COVID-19 in Children

Evaluation of the efficiency and safety of tocilizumab therapy in patients with systemic-onset juvenile idiopathic arthritis: results of a retrospective follow-up

Uveitis Is a Risk Factor for Juvenile Idiopathic Arthritis' Significant Flare in Patients Treated With Biologics

How to identify a patient with autoinflammatory syndrome: Clinical and diagnostic algorithms

A130: Is the CCR5‐delta32 Mutation Protective Against Systemic‐Onset Juvenile Idiopathic Arthritis?

The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study

HEART INJURY IN PATIENTS WITH MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH SARS-CоV-2: A DESCRIPTION OF A SERIES OF CLINICAL CASES

A128: Hierarchical Clustering Methodology for Exploration of Proteomic Profile in Tears: Seeking for Markers of Uveitis Associated With Juvenile Idiopathic Arthritis

A98: Rescue Treatment by Increased Doses of IL‐1 Inhibitors for Macrophage Activation Syndrome in Children With Systemic Juvenile Idiopathic Arthritis

Anemia in children with JIA: is it really driven by hepcidin level, or by a set of factors of a chronic disease

Efficacy of golimumab in children with polyarticular juvenile idi-opathic arthritis

Proteomic Profile of Tears for the Diagnosis of Uveitis Associated with Juvenile Idiopathic Arthritis: Setting Targets to Achieve Results

DIFFERENTIATED APPROACH TO NON-BACTERIAL OSTEOMYELITIS TREATMENT IN CHILDREN: THE RETROSPECTIVE STUDY RESULTS